Overexpression of CD40 in sacral chordomas and its correlation with low tumor recurrence

Onkologie(Czech Republic)

Volumn 36, Issue 10, 2013, Pages 567-571

  Li, Xuefeng ^a   Wang, Sijia ^b   Chen, Yan ^c   Liu, Guifeng ^d,e   Yang, Xiaoyu ^e  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^b China Japan Union Hospital   (China)

^c Second Hospital   (China)

^d Department of Radiology ^*  (China)

^e JILIN UNIVERSITY   (China)

Author keywords

CD40; MVD; Recurrence; Sacral chordoma

Indexed keywords

CD31 ANTIGEN; CD40 ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CHORDOMA; CLINICAL ARTICLE; CORRELATION ANALYSIS; EMBRYONAL TISSUE; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; MALE; NOTOCHORD; RISK FACTOR; SACRAL CHORDOMA; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD40; CHORDOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SACRUM; SPINAL NEOPLASMS; STATISTICS AS TOPIC; TISSUE DISTRIBUTION; UP-REGULATION;

EID: 84885608684     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000355334     Document Type: Article

References (23)

1. Riva P, Crosti F, Orzan F, Dalprà L, Mortini P, Parafioriti A, Pollo B, Fuhrman Conti AM, Miozzo M, Larizza L: Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. Int J Cancer 2003;107:493-497.
2. Sandberg AA, Bridge JA: Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: chondrosarcoma and other cartilaginous neoplasms. Cancer Genet Cytogenet 2003;143:1-31.
3. Eisenberg MB, Woloschak M, Sen C, Wolfe D: Loss of heterozygosity in the retinoblastoma tumor suppressor gene in skull base chordomas and chondrosarcomas. Surg Neurol 1997;47:156-160.
4. Butler MG, Sciadini M, Hedges LK, Schwartz HS: Chromosome telomere integrity of human solid neoplasms. Cancer Genet Cytogenet 1996;86:50-53.
5. Shalaby A, Presneau N, Ye H, Halai D, Berisha F, Idowu B, Leithner A, Liegl B, Briggs TR, Bacsi K, Kindblom LG, Athanasou N, Amary MF, Hogendoorn PC, Tirabosco R, Flanagan AM: The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol 2011;223:336-346.
6. Presneau N, Shalaby A, Ye H, Pillay N, Halai D, Idowu B, Tirabosco R, Whitwell D, Jacques TS, Kindblom LG, Brüderlein S, Möller P, Leithner A, Liegl B, Amary FM, Athanasou NN, Hogendoorn PC, Mertens F, Szuhai K, Flanagan AM: Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J Pathol 2011;223:327-335.
7. Duan Z, Choy E, Nielsen GP, Rosenberg A, Iafrate J, Yang C, Schwab J, Mankin H, Xavier R, Hornicek FJ: Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression. J Orthop Res 2010;28:746-752.
8. Quezada SA, Jarvinen LZ, Lind EF, Noelle R: CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004; 22:307-328.
9. Hill SC, Youde SJ, Man S, Teale GR, Baxendale AJ, Hislop A, Davies CC, Luesley DM, Blom AM, Rickinson AB, Young LS, Eliopoulos AG: Activation of CD40 in cervical carcinoma cell facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol 2005;174:41-50.
10. Biancone L, Cantaluppi V, Camussi G: CD40- CD40L interaction in experimental and human disease. Int J Mol Med 1999;3:343-353.
11. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. Cancer 2000;89:1102-1110.
12. Banchereau J, de Paoli P, Vallé A, Garcia E, Rousset F: Long-term human B cell lines dependent on interleukin 4 and antibody to CD40. Science 1991;251:70-83.
13. Voorzanger-Rousselot N, Alberti L, Blay JY: CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer 2006;6:75.
14. Tong AW, Stone MJ: Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003;10:1-13.
15. Spriggs MK, Armitage RJ, Strockbine L, Clifford KN, Macduff BM, Sato TA, Maliszewski CR, Fanslow WC: Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med 1992;176:1543-1550.
16. Hollenbaugh D, Grosmaire LS, Kullas CD, Chalupny NJ, Braesch-Andersen S, Noelle RJ, Stamenkovic I, Ledbetter JA, Aruffo A: The human T antigen gp39, a member of the TNFa gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co- stimulatory activity. EMBO J 1992;11:4313-4321.
17. Simpson AH, Porter A, Davis A, Griffin A, McLeod RS, Bell RS: Cephalad sacral resection with a combined extended ilioinguinal and posterior approach. J Bone Joint Surg Am 1995;77:405-411.
18. Cheng EY, Ozerdemoglu RA, Transfeldt EE, Thompson RC: Lumbosacral chordoma: prognostic factors and treatment. Spine 1999;24:1639-1645.
19. Yonemoto T, Tatezaki S, Takenouchi T, Ishii T, Satoh T, Moriya H: The surgical management of sacrococcygeal chordoma. Cancer 1999;85:878-883.
20. Schattner EJ, Mascarenhas J, Bishop J, Yoo DH, Chadburn A, Crow MK, Friedman SM: CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cell. Blood 1996;88:1375-1382.
21. Hlatky L, Hahnfeldt P, Folkman J: Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94:883-893.
22. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ: Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 1995;147:33-41.
23. Narita M, Nakao K, Ogino N, Nakahara M, Onishi A, Tsujimoto M: Independent prognostic factors in breast cancer patient. Am J Surg 1998;177:73-75.